SGX-523

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C18H13N7S
Molecular Weight	359.408
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN1C=C(C=N1)C2=NN3C(SC4=CC5=CC=CN=C5C=C4)=NN=C3C=C2

InChI

InChIKey=BCZUAADEACICHN-UHFFFAOYSA-N

InChI=1S/C18H13N7S/c1-24-11-13(10-20-24)16-6-7-17-21-22-18(25(17)23-16)26-14-4-5-15-12(9-14)3-2-8-19-15/h2-11H,1H3

HIDE SMILES / InChI

Molecular Formula	C18H13N7S
Molecular Weight	359.408
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19934279
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/22547164

SGX523 is a selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase. SGX523 was able to inhibit HGF-induced cell migration and cell scatter. SGX523 inhibition of MET in vivo was associated with the dose-dependent inhibition of growth of tumor xenografts derived from human glioblastoma and lung and gastric cancers. The clinical development of SGX523, however, was discontinued at Phase I due to renal toxicity manifested by an early rise of serum blood urea nitrogen and creatinine.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Hepatocyte growth factor receptor 56 Target ID: P08581 Gene ID: 4233.0 Gene Symbol: MET Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/19934279	Inhibitor 8504		2.7 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Solid tumors 147 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22547164	Primary		Phase I 438	Unknown Approved Use Unknown

AUC

Value	Dose	Co-administered	Analyte	Population
10702 ng × h/mL EXPERIMENT https://adisinsight.springer.com/drugs/800026288	5 mg/kg single, oral dose: 5 mg/kg route of administration: Oral experiment type: SINGLE co-administered:		SGX-523 unknown	Rattus norvegicus population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
3.1 h EXPERIMENT https://adisinsight.springer.com/drugs/800026288	5 mg/kg single, oral dose: 5 mg/kg route of administration: Oral experiment type: SINGLE co-administered:		SGX-523 unknown	Rattus norvegicus population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY34071	https://www.001chemical.com/chem/search?q=DY34071
1PlusChem LLC	1P008U05	https://www.1pchem.com/search?query=1P008U05
A2B Chem	AE11333	http://a2bchem.com/prod/AE11333
AChemBlock	A-723	http://www.achemblock.com/catalogsearch/result/?q=A-723
AK Scientific	X7475	https://aksci.com/item_detail.php?cat=X7475
AKOS	AKOS025117577	http://akoscompounds.de/catalogue/AKosSamplesiSSretrieval.php?GUID=4e4caa52-3dca-4da0-b75a-caeae59e1096&IDNUMBERS=AKOS025117577
Angene	AGN-PC-04R650	http://www.angenechemical.com/productshow/AGN-PC-04R650.html
AOBIOUS INC	AOB87181	http://aobious.com/aobious/search?search_query=AOB87181
ApexBio Technology	A1196	https://www.apexbt.com/catalogsearch/result/?q=A1196
AstaTech	C13759	http://astatechinc.com/CPSResult.php?CRNO=C13759
Axon MedChem	1914	https://www.axonmedchem.com/product/1914
BLD Pharm	BD316817	http://www.bldpharm.com/search/Search.html?keyword=BD316817
BOC Sciences	1022150-57-7	http://www.bocsci.com/description.asp?cas=1022150-57-7
Capot Chemical	19151	https://www.capotchem.com/search.do?q=19151
Cayman Chemical	18093	http://www.caymanchem.com/app/template/Product.vm/catalog/18093
ChemShuttle	104832	https://www.chemshuttle.com/catalogsearch/result/?q=104832
eMolecules	32176470	https://orderbb.emolecules.com/search/#?query=32176470
eNovation Chemicals	D573007	https://www.enovationchem.com/Products.asp?SEARCHTEXT=D573007&searchbtn.x=0&searchbtn.y=0
Excenen	EX-A1482	http://www.excenen.com/searchresultlist.php?id=EX-A1482
Exclusive Chemistry	2355	http://www.exchemistry.com/chem-catalog/product-2355.html
KeyOrganics	AS-16292	http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-16292
Lab Network	LN01331015	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01331015
Lab Seeker	SC-86186	http://www.labseeker.com/search.php?keywords=SC-86186&category=0
LabSeeker	SC-86186	http://www.labseeker.com/search.php?keywords=SC-86186&category=0
Matrix Scientific	145221	http://www.matrixscientific.com/145221.html
mcule	MCULE-6498720885	https://mcule.com/MCULE-6498720885/
MedChem Express	HY-12019	https://www.medchemexpress.com/search.html?q=HY-12019&ft=&fa=&fp=
Molcore	MC34071	http://www.molcore.com/CatMC34071.html
Molnova	M10105	https://www.molnova.com/en/serch-list.html?keywords=M10105
MolPort	MolPort-009-679-505	https://www.molport.com/shop/molecule-link/MolPort-009-679-505
MuseChem	I000156	https://www.musechem.com/product/I000156.html
Ryan Scientific	GW788388	https://ryansci.com/products?q=GW788388&list_q=&search_type=exact
ShangHai Biochempartner	BCP000097	http://www.biochempartner.com/search_BCP000097
ShangHai Biochempartner	BCP01772	http://www.biochempartner.com/search_BCP01772
TargetMol	T2293	https://www.targetmol.com/search?keyword=T2293
Tocris	5356	https://www.tocris.com/search.php?Type=QuickSearch&Value=5356
Wonderchem	WD09T96	http://www.wonder-chem.com/search.html?text=WD09T96

PubMed

Title	Date	PubMed
MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth.	2010-09-01	20643778
Species-specific metabolism of SGX523 by aldehyde oxidase and the toxicological implications.	2010-08	20421447
An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth.	2010-01	20015006
SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo.	2009-12	19934279

Patents

Sample Use Guides

In Vivo Use Guide

In a phase I clinical trials SGX523 was administered on an intermittent schedule at a starting dose of 60 mg PO BID for 14 days followed by 7 days of rest. The second protocol explored a continuous 28-day dosing schedule with SGX523 administered at a starting dose of 20 mg PO BID for 28 days without rest.

Route of Administration: Oral

In Vitro Use Guide

To investigate cell migration, A549 cells were plated in 12-well plates (6 × 104 per well) and incubated to confluence. A channel was introduced into the monolayers by scratching with a pipette tip. Various dilutions of the compound were added in starve medium in the presence and absence of HGF (90 ng/mL). Twenty-four hours later, wells were checked for cell migration. Cells were stained and visualized. SGX523 was active in prevention cells migration at concentrations above 50 nM

Substance Class	Chemical Created by `admin` on `Mon Mar 31 22:03:29 GMT 2025` Edited by `admin` on `Mon Mar 31 22:03:29 GMT 2025`
Record UNII	WH8SQN09KJ
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

QUINOLINE, 6-((6-(1-METHYL-1H-PYRAZOL-4-YL)-1,2,4-TRIAZOLO(4,3-B)PYRIDAZIN-3-YL)THIO)-

Preferred Name

English

SGX-523

Code

English

SGX523

Code

English

Code System Code Type Description

CAS

1022150-57-7